GWM
ABCL icon

Geneos Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Geneos Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,087
Closed -$107K – 1993
2022
Q2 		$107K Hold
10,087
– – 0.01% 987
2022
Q1 		$98K Sell
10,087
-200
-2% -$1.89K ﹤0.01% 1102
2021
Q4 		$147K Sell
10,287
-50
-0.5% -$759 0.01% 1007
2021
Q3 		$177K Buy
10,337
+1,997
+24% +$35.3K 0.01% 912
2021
Q2 		$170K Buy
8,340
+250
+3% +$6.89K 0.01% 918
2021
Q1 		$215K Sell
8,090
-12,620
-61% -$503K 0.01% 934
2020
Q4 		$560K Buy
+20,710
New +$947K 0.02% 512

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Geneos Wealth Management's ABCL Position: Q3 2022 in Review

Geneos Wealth Management sold out of AbCellera Biologics (ABCL) in Q3 2022, closing a stake of 10,087 shares — an estimated $107K sold.

Geneos Wealth Management first reported a position in ABCL in Q4 2020 and held it in 7 quarters. The position peaked at $560K in Q4 2020. 190 funds tracked by Wall St. Rank hold ABCL as of Q3 2022.

  • Geneos Wealth Management reported no remaining AbCellera Biologics position as of Q3 2022 after selling out during the quarter.
  • Geneos Wealth Management sold 10,087 AbCellera Biologics shares in Q3 2022, an estimated $107K.
  • Geneos Wealth Management first reported a position in AbCellera Biologics in Q4 2020 and held it in 7 quarters.
  • Geneos Wealth Management's AbCellera Biologics position peaked at $560K in Q4 2020.
  • 190 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.